LeMaitre Vascular senior vice president of operations Trent Kamke sold 2,625 shares of common stock for approximately $285,000 on 11 March 2026, according to an SEC Form 4 filing. The transaction involved exercising fully vested stock options that were immediately converted and sold as common stock. The sale represented 28.22% of Kamke's pre-sale direct holdings, matching the median percentage of holdings traded per sale in his recent activity since December 2024. Following the transaction, Kamke's direct common stock holdings decreased to 6,677 shares, valued at approximately $722,000. LeMaitre Vascular manufactures medical devices and implants for treating peripheral vascular disease. The company reported $249.6 million in trailing twelve-month revenue and $57.7 million in net income, with shares up 30% over one year.

LeMaitre Vascular shares jumped 16.8% after the medical device company reported fourth-quarter 2025 results that exceeded expectations. Revenue reached $64.45 million, up 15.7% year-on-year, whilst earnings per share rose to $0.68 from $0.49 in the prior year's quarter. The company's operating margin expanded to 29.2% from 23.1% a year earlier. LeMaitre provided first-quarter revenue guidance above consensus and forecast full-year 2026 GAAP EPS of $2.91 at the midpoint, surpassing market predictions. The stock has risen 36.4% since the beginning of the year, reaching a new 52-week high of $109.39 per share. Investors who purchased shares five years ago have seen their investment more than double in value.